文献库，生知库 | 链接生命科学的每一步

Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme

在欧洲类风湿性关节炎、强直性脊柱炎、银屑病关节炎和银屑病患者中使用阿达木单抗生物类似药（ABP 501）的真实世界经验：来自 Adelphi 疾病特异性计划的结果

Jin, Ran; Haughton, James M; Goddard, Emily J; Courmier, Delphine; Radziszewski, Waldemar; Meadows, Rachael H; Piercy, James; Cohen, Stanley

强直性脊柱炎

Savings from biosimilars and Medicare formulary access

生物类似药和医保处方集带来的节省

期刊:

影响因子:

doi:10.1093/haschl/qxaf214

Axelsen, Kirsten; Courmier, Delphine; Bai, Ge; Maini, Luca

发表日期：2025

文献求助收藏

Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe

阿达木单抗生物类似药（ABP 501）在欧洲炎症性肠病患者中的真实世界应用经验

期刊:Advances in Therapy

影响因子:4

doi:10.1007/s12325-023-02712-w

Jin, Ran; Nduka, Chidozie; Courmier, Delphine; Knight, Hannah; Meadows, Rachael; Piercy, James; Cummings, J R F; Radziszewski, Waldemar

Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review

对于某些患者而言，基于体重的曲妥珠单抗静脉给药是否优于皮下固定剂量给药？一项系统性范围综述

期刊:Breast

影响因子:7.9

doi:10.1016/j.breast.2021.03.003

Kolberg, Hans-Christian; Jackisch, Christian; Hurvitz, Sara A; Winstone, Julie; Barham, Helen; Hanes, Vladimir; Courmier, Delphine

发表日期：2021

文献求助收藏

A prospective cohort study defining utilities using time trade-offs and the Euroqol-5D to assess the impact of cancer-related lymphedema

一项前瞻性队列研究采用时间权衡法和 EuroQol-5D 量表定义效用值，以评估癌症相关淋巴水肿的影响。

期刊:Cancer

影响因子:5.1

doi:10.1002/cncr.25068

Cheville, Andrea L; Almoza, Mously; Courmier, Janice N; Basford, Jeffrey R

What role for real-world evidence in market access of biosimilars?

真实世界证据在生物类似药市场准入中发挥什么作用？

Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme

在欧洲类风湿性关节炎、强直性脊柱炎、银屑病关节炎和银屑病患者中使用阿达木单抗生物类似药（ABP 501）的真实世界经验：来自 Adelphi 疾病特异性计划的结果

Savings from biosimilars and Medicare formulary access

生物类似药和医保处方集带来的节省

Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe

阿达木单抗生物类似药（ABP 501）在欧洲炎症性肠病患者中的真实世界应用经验

Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review

对于某些患者而言，基于体重的曲妥珠单抗静脉给药是否优于皮下固定剂量给药？一项系统性范围综述

A prospective cohort study defining utilities using time trade-offs and the Euroqol-5D to assess the impact of cancer-related lymphedema

一项前瞻性队列研究采用时间权衡法和 EuroQol-5D 量表定义效用值，以评估癌症相关淋巴水肿的影响。